Diarrhea in Crohn’s disease: investigating the role of the ileal hormone fibroblast growth factor 19. (Q51310817)

3 April 2018

title

Diarrhea in Crohn’s disease: investigating the role of the ileal hormone fibroblast growth factor 19. (English)

1 reference

3 April 2018

0 references

Jonathan D Nolan

1

1 reference

3 April 2018

Ian M Johnston

2

1 reference

3 April 2018

Sanjeev S Pattni

3

1 reference

3 April 2018

Tracy Dew

4

1 reference

3 April 2018

Timothy R Orchard

5

1 reference

3 April 2018

Julian R F Walters

6

1 reference

3 April 2018

publication date

1 February 2015

1 reference

3 April 2018

Journal of Crohn's and Colitis

published in

1 reference

3 April 2018

volume

9

1 reference

3 April 2018

page(s)

125-131

1 reference

3 April 2018

issue

2

1 reference

3 April 2018

A simple index of Crohn's-disease activity

cites work

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJU022

Colonic secretion of water and electrolytes induced by bile acids: perfusion studies in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJU022

Bile acid studies in uncomplicated Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJU022

Human ileal bile acid transporter gene ASBT (SLC10A2) is transactivated by the glucocorticoid receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJU022

c-Fos is a critical mediator of inflammatory-mediated repression of the apical sodium-dependent bile acid transporter.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJU022

Methods for diagnosis of bile acid malabsorption in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJU022

Bile acid malabsorption in Crohn's disease and indications for its assessment using SeHCAT

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJU022

Colesevelam for the treatment of bile acid malabsorption-associated diarrhea in patients with Crohn's disease: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJU022

Serum 7 alpha-hydroxy-4-cholesten-3-one and selenohomocholyltaurine (SeHCAT) whole body retention in the assessment of bile acid induced diarrhoea

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJU022

Bile acid malabsorption assessed by 7 alpha-hydroxy-4-cholesten-3-one in pediatric inflammatory bowel disease: correlation to clinical and laboratory findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJU022

Potent stimulation of fibroblast growth factor 19 expression in the human ileum by bile acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJU022

Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJU022

Effects of chenodeoxycholic acid on the secretion of gut peptides and fibroblast growth factors in healthy humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJU022

A new mechanism for bile acid diarrhea: defective feedback inhibition of bile acid biosynthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJU022

Fibroblast Growth Factor 19 and 7α-Hydroxy-4-Cholesten-3-one in the Diagnosis of Patients With Possible Bile Acid Diarrhea.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJU022

Bile acid malabsorption deactivates pregnane X receptor in patients with Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJU022

Bile acid malabsorption in inflammatory bowel disease: assessment by serum markers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJU022

Fibroblast growth factor 19 in patients with bile acid diarrhoea: a prospective comparison of FGF19 serum assay and SeHCAT retention

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJU022

The response of patients with bile acid diarrhoea to the farnesoid X receptor agonist obeticholic acid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJU022

Kinetics of primary bile acids in patients with non-operated Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJU022

Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJU022

The bile acid receptor FXR is a modulator of intestinal innate immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJU022

Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJU022

A farnesoid x receptor-small heterodimer partner regulatory cascade modulates tissue metalloproteinase inhibitor-1 and matrix metalloprotease expression in hepatic stellate cells and promotes resolution of liver fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJU022

The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJU022

Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJU022

Pharmacological activation of the bile acid nuclear farnesoid X receptor is feasible in patients with quiescent Crohn's colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJU022

Farnesoid X receptor (FXR) activation and FXR genetic variation in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FECCO-JCC%2FJJU022

21 January 2018

Identifiers

DOI

10.1093/ECCO-JCC/JJU022

1 reference

3 April 2018

PubMed ID

25518063

1 reference

3 April 2018